Cell Biotech's sales in the first quarter of this year decreased by 13.9% compared to the same period last year, totaling 11.2 billion won, while operating profit increased by 27.1% to 1.4 billion won, the company announced on the 9th.
The company noted that sales have slightly decreased due to a temporary downturn in the domestic health supplement market and intensified price competition, but higher revenue from exports offset this, leading to improved profit margins.
Cell Biotech's main brand, "DUOLAC," is exported to 55 countries worldwide, including Denmark, the home country of probiotics, based on its excellent quality and safety. It accounted for 25.9 billion won of the total probiotic exports from South Korea, which reached 59.6 billion won in 2023, securing the number one position in exports for 11 consecutive years. This year, cumulative exports to Indonesia surpassed $30 million.
The company is focusing on diversifying distribution channels and expanding global partnerships to broaden its market while developing the microbiome colorectal cancer drug "PP-P8." PP-P8 is an oral gene therapy using K-probiotics, developed in an entirely different way from existing drugs, and clinical trials for this innovative drug have commenced at Seoul National University Hospital.